Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab
Authors / Editors
Research Areas
No matching items found.
Publication Details
Output type: Journal article
Author list: Voigt M., Braig F., Göthel M., Schulte A., Lamszus K., Bokemeyer C., Binder M.
Publisher: Elsevier
Publication year: 2012
Journal: Neoplasia (1522-8002)
Volume number: 14
Issue number: 11
Start page: 1023
End page: 1031
Number of pages: 9
ISSN: 1522-8002
eISSN: 1476-5586
URL: http://api.elsevier.com/content/abstract/scopus_id:84869178810
Unpaywall Data
Open access status: gold
Full text URL: https://doi.org/10.1593/neo.121242
Abstract
Cetuximab and panitumumab, two antibodies targeting the extracellular domain of the epidermal growth factor receptor (EGFR), are of major clinical importance particularly in the treatment of metastatic colorectal cancer. As patients may acquire resistance-mediating mutations within the extracellular EGFR domain, functional dissection of the exact binding sites of EGFR targeting antibodies may help predict treatment responses. We therefore assessed the epitope recognition of panitumumab by screening phage-displayed random cyclic 7mer and linear 12mer peptide libraries on this antibody. Phage screenings revealed two strong, potentially epitope-mimicking consensus motifs targeted by panitumumab. A computational approach was used to map the sequences back to the potential epitope region on domain III of EGFR. The presumed epitope regions (386) WPEXRT (391) and a biochemically similar though discontinuous region P349-F352-D355 on a neighboring loop of domain III could be confirmed as part of the functionally relevant binding site of panitumumab by site-directed mutational analysis. To more accurately differentiate the panitumumab epitope from the previously characterized cetuximab epitope, binding studies were performed on a broad range of additional mutants. Taken together, this analysis revealed two large, partially overlapping functional epitopes consisting of 17 critical amino acid positions. Four of these positions were selectively targeted by cetuximab (I467, S468, Q408, and H409), whereas another four were selectively recognized by panitumumab (W386, E388, R390, and T391). In view of the clinical significance of extracellular domain mutations, our data may help guide treatment decisions in selected patients receiving EGFR-targeted therapies. © 2012 Neoplasia Press, Inc. All rights reserved.
Keywords
No matching items found.
Documents
No matching items found.
